Key Highlights
- IDEAYA Biosciences unveiled successful Phase 2/3 clinical data for its darovasertib and crizotinib combination therapy in metastatic uveal melanoma patients
- The dual-drug regimen achieved a median progression-free survival of 6.9 months compared to 3.1 months with conventional therapy
- Trial participants receiving the combination experienced a 58% decrease in disease progression risk
- The combination therapy produced an overall response rate of 37.1% versus only 5.8% for standard treatment — including 5 complete responses in the experimental arm and zero in the control group
- The company intends to submit a New Drug Application (NDA) to the FDA during the latter half of 2026
Shares of IDEAYA Biosciences (IDYA) skyrocketed during premarket hours on Monday following the biotechnology firm’s announcement of encouraging Phase 2/3 clinical trial outcomes for its innovative two-drug regimen designed to combat metastatic uveal melanoma — an uncommon and challenging-to-treat cancer originating in the eye.
IDEAYA Biosciences, Inc., IDYA
The clinical study evaluated the combination of darovasertib paired with crizotinib. Findings demonstrated that this drug pairing more than doubled the median progression-free survival when compared against current standard-of-care treatment approaches.
Participants receiving the combination treatment achieved a median PFS of 6.9 months. In contrast, those on standard therapy reached only 3.1 months. This substantial difference successfully satisfied the study’s primary endpoint.
Furthermore, the combination regimen reduced the risk of cancer progression by 58%. This figure represents a significant milestone that typically captures considerable attention from oncology-focused investors.
Impressive Secondary Outcome Measures
The trial’s secondary endpoints delivered equally compelling results. The overall response rate registered at 37.1% for patients receiving the darovasertib combination, substantially outperforming the mere 5.8% response rate observed with standard care.
Five participants in the combination treatment group experienced complete responses. Meanwhile, the standard-care cohort recorded no complete responses whatsoever.
The median duration of response among combination therapy patients reached 6.8 months. Researchers characterized the drug combination as well-tolerated, featuring a safety profile deemed manageable.
Additionally, preliminary data suggested a favorable overall survival trend for the combination approach versus standard treatment, although comprehensive data regarding this metric remains immature at this stage.
Metastatic uveal melanoma has traditionally presented extremely limited effective therapeutic options. These trial outcomes establish darovasertib as a potentially first-in-class treatment for this serious condition.
Regulatory Submission Targeted for Second Half 2026
IDEAYA announced its intention to file a New Drug Application with the FDA during the second half of 2026, leveraging these positive trial findings.
This projected timeline positions a potential regulatory approval decision around 2027, contingent upon the FDA’s review pace.
IDYA stock climbed as much as 26.36% during premarket trading, touching $38.60, based on Benzinga Pro data. Initial reports indicated approximately 15% gains, with shares trading around $35.
The equity had already been hovering near its 52-week peak of $41.02 prior to Monday’s disclosure. Throughout the past year, IDYA has appreciated roughly 78%.
The broader equity market displayed weakness on Monday, with S&P 500 futures declining approximately 0.6% during the time of the premarket rally.
IDEAYA intends to unveil comprehensive trial data at a forthcoming medical conference, with additional details anticipated later in 2026.
